Basilio-de Leo CI, Castillejos-Molina R, Uribe-Uribe N, Sotomayor-Zavaleta M, Feria-Bernal G, Gabilondo-Navarro F, Rodríguez-Covarrubias F

Language: Spanish
References: 48
Page: 151-156
PDF size: 387.09 Kb.

ABSTRACT

Aims: To evaluate the prognostic role of clinicopathologic variables in patients with renal cell cancer (RCC) that were surgically treated.
Material and methods: We retrospectively analyzed the hospital database of 440 patients with renal tumors, evaluating clinical as well as histopathologic variables. The main outcome was cancer-specific survival (CSS) that was determined using the Kaplan-Meier method. Univariate and multivariate analyses were carried out to establish the prognostic factors.
Results: A total of 370 patients with RCC were identified covering the period of time from March 1980 to July 2011. The mean follow-up time was 55.4 months. There was a 23.2% mortality due to cancer and, compared with the surviving patients, those that died presented with larger tumors (p‹0.0001), of higher grade (p‹0.0001), and with a greater frequency of lymphovascular invasion (p‹0.0001). The CSS at five and 10 years was 97.2% and 97.2% in stage I, 77.8% and 68.1% in stage II, 62.7% and 49.4% in stage III, and 18.4% and 6.0% in stage IV (p‹0.0001), respectively. All variables were associated with CSS in the univariate analysis and in the multivariate analysis nuclear grade, lymph node invasion, tumor diameter, and the presence of metastasis maintained an independent association with survival.
Conclusions: We corroborated the prognostic potential of nuclear grade, tumor diameter, Eastern Cooperative Oncology Group (ECOG) score, lymph node invasion, and the presence of metastasis.

REFERENCES

1. Colli JL, Busby JE, Amling CL. Renal cell carcinoma rates compared with health status and behavior in the United States. Urology 2009;73(2):431-436.

2. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2006. CA Cancer J Clin 2006;56(2):106-130.

3. Escudier B, Kataja V. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20 Suppl 4:81-82.

4. DeCastro GJ, McKiernan JM. Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am 2008;35(4):581-592.

5. Jewett M, Zuniga A. Renal tumor natural history: the Rationale and Role for Active Surveillance. Urol Clin North Am 2008;35(4):627-634.

6. Wein AJ, Kavoussi LR, Novick AC, et al. Campbell-Walsh Urology. 10th ed. Philadelphia, USA. Saunders Elsevier. 2011. 1419-1448.

7. Nelson EC, Evans CP, Lara PN. Renal cell carcinoma: Current status and emerging therapies. Cancer Treat Rev 2007;33(3):299-313.

8. Ljungberg B, Cowan N, Hanbury DC, et al. Guidelines on Renal Cell Carcinoma. European Association of Urology. Eur Urol 2010;58(3):398-406.

9. Harada K, Sakai I, Ishimura T, et al. Clinical symptoms in localized renal cell carcinoma reflect its invasive potential: Comparative study between incidentally detected and symptomatic diseases. Urol Oncol 2006;24(3):201-206.

10. Chen D, Uzzo R. Evaluation and Management of the Renal Mass. Med Clin North Am 2011;95(1):179-189.

11. Furniss D, Harnden P, Ali N, et al. Prognostic factors for renal cell carcinoma. Cancer Treat Rev 2008;34(5):407-426.

12. Lane BR, Kattan MW. Prognostic Models and Algorithms in Renal Cell Carcinoma. Urol Clin North Am 2008;35(4):613-625.

13. Herr HW. A History of Partial Nephrectomy for Renal Tumors. J Urol 2005;173(3):705-708.

14. Sengupta S, Zincke H. Lessons learned in the surgical management of renal cell carcinoma. Urology 2005;66(5 Suppl):36-42.

15. Rodríguez F, Gabilondo B, Gabilondo F, et al. Partial nephrectomy for renal tumor using selective parenchymal clamping. Int Urol Nephrol 2007;39(1):43-46.

16. Gomez O, Rodríguez F, Sotomayor M, et al. Prognostic factors in renal-cell carcinoma treated surgically: analysis of a cohort of 345 cases. Rev Invest Clin 2011;63(1):12-17.

17. Rodríguez F, Castillejos R, Sotomayor M, et al. Impact of lymph node invasion and sarcomatoid differentiation on the survival of patients with locally advanced renal cell carcinoma. Urol Int 2010;85(1):23-29.

18. Downs TM, Schultzel M, Shi H, et al. Renal cell carcinoma: Risk assessment and prognostic factors for newly diagnosed patients. Crit Rev Oncol Hematol 2009;70(1):59-70.

19. Méjean A, Oudard S, Thiounn N. Prognostic Factors of Renal Cell Carcinoma. J Urol. 2003;169(3):821-827.

20. Ficarra V, Galfano A, Verhoest G, et al. Prognostic Factors and Staging systems for Renal Cell Carcinoma. Eur Urol 2007;Suppl 6:623-629.

21. Srigley JR, Hutter RVP, Gelb AB, et al. Current prognostic factors-Renal cell carcinoma. Cancer 1997;80(5):994-996.

22. Leveridge MJ, Jewett M. Recent Developments in kidney cancer. Can Urol Assoc J 2011;5(3):195-203.

23. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of Renal Cell Carcinoma. J Urol 2001;166(5):1611-1623.

24. Masuda H, Kurita Y, Fukuta K, et al. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol 1998;5(5):418-422.

25. Dimashkieh H, Lohse C, Blute M, et al. Extranodal Extension in Regional Lymph Nodes is Associated With Outcome in Patients With Renal Cell Carcinoma. J Urol 2006;176(5):1978-1982.

26. Jalón A, Álvarez M, Fernández JM, Martín JL, et al. Renal cell carcinoma: prognostic factors and stratification. Arch Esp Urol 2007;60(2):125-136.

27. Zubac D, Bostad L, Seidal T, et al. The prognostic relevance of interactions between venous invasion, lymph node involvement and distant metastases in renal cell carcinoma after radical nephrectomy. BMC Urol 2008;8:19.

28. Leibovich, BC, Blute ML, Cheville JC, et al. Prediction of Progression after Radical Nephrectomy for Patients with Clear Cell Renal Cell Carcinoma. Cancer 2003;97(7):1663-1671.

29. Lohse CM, Cheville JC. A Review of Prognostic Pathologic Features and Algorithms for Patients Treated Surgically for Renal Cell Carcinoma. Clin Lab Med 2005;25(2):433-464.

30. Bukowski RM. Prognostic Factors for Survival in Metastatic Renal Cell Carcinoma. Cancer 2009;115(10 Suppl):2273-2281.

31. Lambert EH, Pierorazio PM, Shabsigh A, et al. Prognostic Risk Stratification and Clinical Outcomes in Patients Undergoing Surgical Treatment for Renal Cell Carcinoma with Vascular Tumor Thrombus. Urology 2007;69(6):1054-1058.

32. Zisman A, Pantuck AJ, Dorey F. Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System. J Clin Oncol 2001;19(6):1649-1657.

33. Novara G, Martignoni G, Artibani W, et al. Grading Systems in Renal Cell Carcinoma. J Urol 2007;177(2):430-436.

34. Ficarra V, Prayer-Galetti T, Novella G, et al. Incidental detection beyond pathological factors as prognostic predictor of renal cell carcinoma. Eur Urol 2003;43(6):663-669.

35. Patard J, Leray E, Rioux-Leclercq N, et al. Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience. J Clin Oncol 2005;23(12):2763-2771.

36. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol 2002;168(6):2395-2400.

37. Ficarra V, Martignoni G, Lohse C, et al. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. J Urol 2006;175(4):1235-1239.

38. Ficarra V, Martignoni G, Maffei N, et al. Original and Reviewed Nuclear Grading According to the Fuhrman System: A Multivariate Analysis of 388 Patients with Conventional Renal Cell Carcinoma. Cancer 2005;103(1):68-75.

39. Klatte T, Patard J, de Martino M, et al. Tumor Size Does Not Predict Risk of Metastatic Disease or Prognosis of Small Renal Cell Carcinomas. J Urol 2008;179(5):1719-1726.

40. Thompson RH, Hill J, Babayev Y, et al. Risk of metastatic renal cell carcinoma according to tumor size. J Urol 2009;182(1):41-45.

41. Dall’Oglio MF, Ribeiro LA, Antunes A, et al. Microvascular Tumor Invasion, Tumor Size and Fuhrman Grade: A Pathological Triad for Prognostic Evaluation of Renal Cell Carcinoma. J Urol 2007;178(2):425-428.

42. Karakiewicz PI, Suardi N, Capitanio U, et al. Conditional Survival Predictions After Nephrectomy for Renal Cell Carcinoma. J Urol 2009;182(6):2607-2612.

43. Miyagawa T, Shimazui T, Hinotsu S, et al. Does Tumor Size or Microvascular Invasion Affect Prognosis in Patients with Renal Cell Carcinoma? Jpn J Clin Oncol 2007;37(3):197-200.

44. Kim HL, Han KR, Zisman A, et al. Cachexia-like symptoms predict a worse prognosis in localized T1 renal cell carcinoma. J Urol 2004;171(5):1810-1813.

45. Dall’Oglio MF, Arap MA, Antunes A, et al. Impact of Clinicopathological Parameters in Patients Treated for Renal Cell Carcinoma. J Urol 2007;177(5):1687-1691.

46. Rodriguez-Jasso VH, Serrano-Brambila E, Maldonado-Alcaraz E. Prognostic factors in localized and locally advanced renal cancer. Actas Urol Esp 2008;32(3):320-324.

47. Mota-Romero JV, Castillo G, Monjaraz G, et al. Renal cell carcinoma: Retrospective analysis of 106 cases. Rev Mex Urol 1999;59(2):63-67.

48. Santana-Ríos Z, Urdiales-Ortiz A, Camarena-Reynoso H, et al. Renal cell carcinoma, pathological prognostic factors and new stratification strategies. Rev Mex Urol 2011;71(4):218-224.